A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma

Trial Profile

A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Propranolol (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 03 Jan 2018 New trial record
    • 02 Jan 2018 Planned initiation date changed from 30 Dec 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top